Global spending for recreational pot will reach US$16.9 billion in 2019, a new study says.
The study, done collaboratively by the Arcview Group and BDS Analytics, indicates that in 2018 adult-use cannabis sales racked in US$12.2 billion. The study projects a jump of 38 percent in spending this year.
Findings of the research were made public by the Arcview Group on Tuesday (January 15).
Troy Dayton, CEO of the Arcview Group, called 2018 “a year of historic importance” for cannabis, crediting the entry of established firms from industries such as alcohol and tobacco, along with the legalization of hemp and its derivatives thanks to a new US$867-billion farm bill.
Beyond 2019, the Arcview Group is calling for recreational cannabis sales to hit US$31.3 billion in 2022.
That pace of growth would amount to a 26.7-percent compound annual growth rate over a five-year timeframe starting in 2017, when sales reached US$9.5 billion.
Multi-state operators in the US aid sector growth
According to the study, multi-state operators of cannabis assets in the US boomed in 2018, with five of these companies reaching valuations of over US$100 million.
The report calls this activity a “gold-rush” for these operators, and indicates that those companies reached a combined market capitalization of US$5.5 billion in 2018.
Meanwhile, in Canada five licensed producers (LPs) had reached a combined value of nearly US$20 billion by the end of the year.
Due to the federal illegality of cannabis in the US, companies looking to raise capital and pursue opportunities in legal marijuana states must do so on the Canadian Securities Exchange (CSE).
As cannabis stocks flock to the CSE, the exchange is seeing interest in these stocks raise. According to a report from The Globe and Mail, the CSE attracted C$2.73 billion from the rapidly expanding cannabis sector in the US in 2018. That amount represents over half of the investment seen on the whole exchange throughout the year.
“According to S&P Global Intelligence, there were 32 CSE companies with a market capitalization of at least [C]$100-million as of [January 11]; 31 of those, including the 17 biggest, were in the cannabis business,” the report indicates.
Hemp play raising in value
Since the passing of the farm bill, several Canadian cannabis companies have disclosed plans to pursue markets in the US with hemp products, with Canopy Growth (NYSE:CGC,TSX:WEED) among the entrants.
The Canadian LP obtained a production license in the state of New York this week and officialized its intentions to deploy between US$100 and US$150 million in the state to produce these products.
Research firm Brightfield Group projects the passing of the bill will set the industry for hemp and its derivatives on the way to making over US$20 billion in sales by 2022.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.